Rani Therapeutics struck a deal with Chugai Pharmaceutical to combine Rani’s robotic oral delivery capsule with Chugai’s experimental rare‑disease antibody, a pact valued at up to $1.08 billion. The agreement grants Chugai access to Rani’s oral biologic platform for at least one program and signals continued industry interest in noninvasive biologic delivery. Rani disclosed the partnership alongside corporate updates and framed the pact as a commercialization step that could broaden the market for antibody therapies if oral delivery proves clinically and operationally viable.